Bone metastases in advanced prostate cancer. Management
6/20/22, 12:19 AM 17128PSA: prostate-specific antigen; HR: hazard ratio; IV: intravenous; GM-CSF: granulocyte-macrophagecolony-stimulating factor.* Docetaxel is also indicated for castration-sensitive disease in combination with androgendeprivation therapy for metastatic prostate cancer.References: 1. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostatecancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.Lancet Oncol 2012; 13:983.2. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone inchemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survivalanalysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16:152.3. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl JMed 2012; 367:1187.4. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl JMed 2010; 363:411.5. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advancedprostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242.6. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistantprostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376:1147.7. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl JMed 2013; 369:213.Graphic 127197 Version 2.0https://www.uptodate.com/contents/17128/print 22/27
6/20/22, 12:19 AM 17128Physical properties of radionuclides for patients with bone metastasesRadionuclide Particle Physical half-life Particle energy223radium Alpha 11.4 days 5.99 MeV153samarium Beta 1.9 days 0.81 MeV89strontium Beta 50.5 days 1.46 MeV32phosphorusBeta 14.3 days 1.71 MeVGraphic 53847 Version 4.0https://www.uptodate.com/contents/17128/print 23/27
- Page 1 and 2: 6/20/22, 12:19 AM 17128®Official r
- Page 3 and 4: 6/20/22, 12:19 AM 17128metastatic c
- Page 5 and 6: 6/20/22, 12:19 AM 17128surgery inte
- Page 7 and 8: 6/20/22, 12:19 AM 17128Agency to re
- Page 9 and 10: 6/20/22, 12:19 AM 17128difference i
- Page 11 and 12: 6/20/22, 12:19 AM 17128post hoc ana
- Page 13 and 14: 6/20/22, 12:19 AM 17128assigned to
- Page 15 and 16: 6/20/22, 12:19 AM 17128●●●●
- Page 17 and 18: 6/20/22, 12:19 AM 17128REFERENCES1.
- Page 19 and 20: 6/20/22, 12:19 AM 17128Zoledronic A
- Page 21: 6/20/22, 12:19 AM 17128GRAPHICSOver
- Page 25 and 26: 6/20/22, 12:19 AM 17128placebo plus
- Page 27: 6/20/22, 12:19 AM 17128Contributor
6/20/22, 12:19 AM 17128
PSA: prostate-specific antigen; HR: hazard ratio; IV: intravenous; GM-CSF: granulocyte-macrophage
colony-stimulating factor.
* Docetaxel is also indicated for castration-sensitive disease in combination with androgen
deprivation therapy for metastatic prostate cancer.
References:
1. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate
cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
Lancet Oncol 2012; 13:983.
2. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in
chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival
analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16:152.
3. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J
Med 2012; 367:1187.
4. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J
Med 2010; 363:411.
5. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced
prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242.
6. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant
prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;
376:1147.
7. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J
Med 2013; 369:213.
Graphic 127197 Version 2.0
https://www.uptodate.com/contents/17128/print 22/27
Change language